Abstract Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is
associated with severe morbidity and increased mortality. Cannabis-based therapies have …

Background: SCN1A is one of the most common epilepsy genes. About 80% of SCN1A
gene mutations cause Dravet syndrome (DS), which is a severe and catastrophic epileptic …

Objective Add‐on cannabidiol (CBD) significantly reduced seizures associated with Dravet
syndrome (DS) in a randomized, double‐blind, placebo‐controlled trial: GWPCARE1 Part B …

Dravet syndrome is a severe developmental and epileptic encephalopathy characterised by
refractory seizures and cognitive dysfunction. The treatment is challenging, not least …

Objective Cannabidiol (CBD) has been approved by the US Food and Drug Administration
(FDA) to treat intractable childhood epilepsies, such as Dravet syndrome and Lennox …

Purpose To assess the impact of fenfluramine (FFA) on the expected mortality incidence,
including sudden unexpected death in epilepsy (SUDEP), in persons with Dravet syndrome …

Dravet syndrome is a catastrophic, pharmacoresistant epileptic encephalopathy. Disease
onset occurs in the first year of life, followed by developmental delay with cognitive and …

Dravet syndrome is an archetypal rare severe epilepsy, considered 'monogenic', typically
caused by loss-of-function SCN1A variants. Despite a recognizable core phenotype, its …

ABSTRACT RNA therapeutics comprise a diverse group of oligonucleotide-based drugs
such as antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and short …

Dravet syndrome (DS), also known as severe myoclonic epilepsy of infancy (SMEI), is one of
the rare early childhood intractable epileptic encephalopathies associated with pleomorphic …